;PMID: 8561796
;source_file_1790.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..53] = [t:0..53]
;1)sentence:[e:59..230] = [t:59..230]
;2)section:[e:234..283] = [t:234..283]
;3)section:[e:287..364] = [t:287..364]
;4)sentence:[e:368..502] = [t:368..502]
;5)sentence:[e:503..625] = [t:503..625]
;6)sentence:[e:626..752] = [t:626..752]
;7)sentence:[e:753..851] = [t:753..851]
;8)sentence:[e:853..1069] = [t:853..1069]
;9)sentence:[e:1070..1164] = [t:1070..1164]
;10)sentence:[e:1165..1240] = [t:1165..1240]
;11)sentence:[e:1242..1334] = [t:1242..1334]
;12)sentence:[e:1335..1480] = [t:1335..1480]
;13)sentence:[e:1481..1558] = [t:1481..1558]
;14)sentence:[e:1559..1829] = [t:1559..1829]
;15)section:[e:1833..1877] = [t:1833..1877]

;section 0 Span:0..53
;Biochem Biophys Res Commun. 1996 Jan 17;218(2):562-9.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res)
        (NNP:[20..26] Commun) (.:[26..27] .) (CD:[28..32] 1996)
        (CC:[33..36] Jan) (CD:[37..43] 17;218) (-LRB-:[43..44] -LRB-)
        (CD:[44..45] 2) (-RRB-:[45..46] -RRB-) (::[46..47] :) (CD:[47..50] 562)
        (::[50..51] -) (CD:[51..53] 9.)))

;sentence 1 Span:59..230
;Piperine impairs cytochrome P4501A1 activity by direct interaction with the 
;enzyme and not by down regulation of CYP1A1 gene expression in the rat
;hepatoma  5L cell line.
;[59..67]:substance:"Piperine"
;[76..94]:cyp450:"cytochrome P4501A1"
;[136..142]:cyp450:"enzyme"
;[173..179]:cyp450:"CYP1A1"
(SENT
  (S-HLN
    (NP-SBJ (NN:[59..67] Piperine))
    (VP (VBZ:[68..75] impairs)
      (NP
        (NML (NN:[76..86] cytochrome) (NN:[87..94] P4501A1))
        (NN:[95..103] activity))
      (PP-MNR
        (PP (IN:[104..106] by)
          (NP
            (NP (JJ:[107..113] direct) (NN:[114..125] interaction))
            (PP (IN:[126..130] with)
              (NP (DT:[131..134] the) (NN:[136..142] enzyme)))))
        (CONJP (CC:[143..146] and) (RB:[147..150] not))
        (PP (IN:[151..153] by)
          (NP
            (NP (RB:[154..158] down) (NN:[159..169] regulation))
            (PP (IN:[170..172] of)
              (NP (NN:[173..179] CYP1A1) (NN:[180..184] gene)
                  (NN:[185..195] expression)))
            (PP-LOC (IN:[196..198] in)
              (NP (DT:[199..202] the) (NN:[203..206] rat)
                  (NN:[207..215] hepatoma) (NN:[217..219] 5L)
                  (NN:[220..224] cell) (NN:[225..229] line)))))))
    (.:[229..230] .)))

;section 2 Span:234..283
;Reen RK, Roesch SF, Kiefer F, Wiebel FJ, Singh J.
(SEC
  (FRAG (NNP:[234..238] Reen) (NNP:[239..241] RK) (,:[241..242] ,)
        (NNP:[243..249] Roesch) (NNP:[250..252] SF) (,:[252..253] ,)
        (NNP:[254..260] Kiefer) (NNP:[261..262] F) (,:[262..263] ,)
        (NNP:[264..270] Wiebel) (NNP:[271..273] FJ) (,:[273..274] ,)
        (NNP:[275..280] Singh) (NNP:[281..283] J.)))

;section 3 Span:287..364
;Biochemistry Section, Regional Research Laboratory (CSIR), Jammu Tawi,
;India.
(SEC
  (FRAG (NNP:[287..299] Biochemistry) (NNP:[300..307] Section) (,:[307..308] ,)
        (NNP:[309..317] Regional) (NNP:[318..326] Research)
        (NNP:[327..337] Laboratory) (-LRB-:[338..339] -LRB-)
        (NNP:[339..343] CSIR) (-RRB-:[343..344] -RRB-) (,:[344..345] ,)
        (NNP:[346..351] Jammu) (NNP:[352..356] Tawi) (,:[356..357] ,)
        (NNP:[358..363] India) (.:[363..364] .)))

;sentence 4 Span:368..502
;Modulation of benzo(a)pyrene (BP) metabolism and regulation of CYP1A1 gene 
;expression by piperine in 5L cells in culture was studied.
;[382..396]:substance:"benzo(a)pyrene"
;[398..400]:substance:"BP"
;[431..437]:cyp450:"CYP1A1"
;[458..466]:substance:"piperine"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP
          (NP (NN:[368..378] Modulation))
          (PP (IN:[379..381] of)
            (NP
              (NML
                (NML (NN:[382..396] benzo-LRB-a-RRB-pyrene))
                (NML (-LRB-:[397..398] -LRB-) (NN:[398..400] BP)
                     (-RRB-:[400..401] -RRB-)))
              (NN:[402..412] metabolism))))
        (CC:[413..416] and)
        (NP
          (NP (NN:[417..427] regulation))
          (PP (IN:[428..430] of)
            (NP (NN:[431..437] CYP1A1) (NN:[438..442] gene)
                (NN:[444..454] expression)))))
      (PP (IN:[455..457] by)
        (NP (NN:[458..466] piperine)))
      (PP-LOC (IN:[467..469] in)
        (NP
          (NP (NN:[470..472] 5L) (NNS:[473..478] cells))
          (PP-LOC (IN:[479..481] in)
            (NP (NN:[482..489] culture))))))
    (VP (VBD:[490..493] was)
      (VP (VBN:[494..501] studied)
        (NP-1 (-NONE-:[501..501] *))))
    (.:[501..502] .)))

;sentence 5 Span:503..625
;Treatment of cultures  with 60 microM piperine for different time periods
;inhibited metabolism of BP by  50% within 4-8 h.
;[531..533]:quantitative-value:"60"
;[534..540]:quantitative-units:"microM"
;[541..549]:substance:"piperine"
;[601..603]:substance:"BP"
;[608..611]:quantitative-value:"50%"
;[619..622]:quantitative-value:"4-8"
;[623..624]:quantitative-units:"h"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[503..512] Treatment))
      (PP (IN:[513..515] of)
        (NP (NNS:[516..524] cultures)))
      (PP (IN:[526..530] with)
        (NP
          (NML (CD:[531..533] 60) (NN:[534..540] microM))
          (NN:[541..549] piperine)))
      (PP (IN:[550..553] for)
        (NP (JJ:[554..563] different) (NN:[564..568] time)
            (NNS:[569..576] periods))))
    (VP (VBD:[577..586] inhibited)
      (NP
        (NP (NN:[587..597] metabolism))
        (PP (IN:[598..600] of)
          (NP (NN:[601..603] BP))))
      (PP-EXT (IN:[604..606] by)
        (NP (CD:[608..610] 50) (NN:[610..611] %)))
      (PP-TMP (IN:[612..618] within)
        (NP
          (QP (CD:[619..620] 4) (HYPH:[620..621] -) (CD:[621..622] 8))
          (NN:[623..624] h))))
    (.:[624..625] .)))

;sentence 6 Span:626..752
;Piperine uptake in 5L cells attained saturation plateau at 8 h  and this
;related with the maximal impairment of BP metabolism.
;[626..634]:substance:"Piperine"
;[685..686]:quantitative-value:"8"
;[687..688]:quantitative-units:"h"
;[738..740]:substance:"BP"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[626..634] Piperine) (NN:[635..641] uptake))
        (PP-LOC (IN:[642..644] in)
          (NP (NN:[645..647] 5L) (NNS:[648..653] cells))))
      (VP (VBD:[654..662] attained)
        (NP (NN:[663..673] saturation) (NN:[674..681] plateau))
        (PP-TMP (IN:[682..684] at)
          (NP (CD:[685..686] 8) (NN:[687..688] h)))))
    (CC:[690..693] and)
    (S
      (NP-SBJ (DT:[694..698] this))
      (VP (VBD:[699..706] related)
        (PP-CLR (IN:[707..711] with)
          (NP
            (NP (DT:[712..715] the) (JJ:[716..723] maximal)
                (NN:[724..734] impairment))
            (PP (IN:[735..737] of)
              (NP (NN:[738..740] BP) (NN:[741..751] metabolism)))))))
    (.:[751..752] .)))

;sentence 7 Span:753..851
;Exposure of cell  cultures to piperine for 24 h indicated activation of
;CYP1A1 gene transcription.
;[783..791]:substance:"piperine"
;[796..798]:quantitative-value:"24"
;[799..800]:quantitative-units:"h"
;[825..831]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[753..761] Exposure))
      (PP (IN:[762..764] of)
        (NP (NN:[765..769] cell) (NNS:[771..779] cultures)))
      (PP (TO:[780..782] to)
        (NP (NN:[783..791] piperine)))
      (PP-TMP (IN:[792..795] for)
        (NP (CD:[796..798] 24) (NN:[799..800] h))))
    (VP (VBD:[801..810] indicated)
      (NP
        (NP (NN:[811..821] activation))
        (PP (IN:[822..824] of)
          (NP (NN:[825..831] CYP1A1) (NN:[832..836] gene)
              (NN:[837..850] transcription)))))
    (.:[850..851] .)))

;sentence 8 Span:853..1069
;There was a 10-fold increase in CYP1A1mRNA and an approximately 7-fold
;increase  in arylhydrocarbon hydroxylase (AHH) activity, while treatment with
; benzanthacene (BA) increased CYP1A1mRNA by 86- and AHH by 56-fold.
;[865..872]:quantitative-value:"10-fold"
;[885..895]:substance:"CYP1A1mRNA"
;[903..923]:quantitative-value:"approximately 7-fold"
;[937..964]:substance:"arylhydrocarbon hydroxylase"
;[966..969]:substance:"AHH"
;[1003..1016]:substance:"benzanthacene"
;[1018..1020]:substance:"BA"
;[1032..1042]:substance:"CYP1A1mRNA"
;[1046..1049]...[1064..1068]:quantitative-value:"86-"..."fold"
;[1054..1057]:substance:"AHH"
;[1061..1068]:quantitative-value:"56-fold"
(SENT
  (S
    (NP-SBJ (EX:[853..858] There))
    (VP (VBD:[859..862] was)
      (NP-PRD
        (NP
          (NP (DT:[863..864] a)
            (QP (CD:[865..867] 10) (HYPH:[867..868] -) (JJ:[868..872] fold))
            (NN:[873..881] increase))
          (PP (IN:[882..884] in)
            (NP (NN:[885..895] CYP1A1mRNA))))
        (CC:[896..899] and)
        (NP
          (NP (DT:[900..902] an)
            (QP (RB:[903..916] approximately) (CD:[917..918] 7)
                (HYPH:[918..919] -) (JJ:[919..923] fold))
            (NN:[924..932] increase))
          (PP (IN:[934..936] in)
            (NP
              (NML
                (NML (NN:[937..952] arylhydrocarbon) (NN:[953..964] hydroxylase))
                (NP (-LRB-:[965..966] -LRB-) (NN:[966..969] AHH)
                    (-RRB-:[969..970] -RRB-)))
              (NN:[971..979] activity)))))
      (,:[979..980] ,)
      (SBAR-ADV (IN:[981..986] while)
        (S
          (NP-SBJ
            (NP (NN:[987..996] treatment))
            (PP (IN:[997..1001] with)
              (NP
                (NP (NN:[1003..1016] benzanthacene))
                (NP (-LRB-:[1017..1018] -LRB-) (NN:[1018..1020] BA)
                    (-RRB-:[1020..1021] -RRB-)))))
          (VP
            (VP (VBD:[1022..1031] increased)
              (NP=3 (NN:[1032..1042] CYP1A1mRNA))
              (PP=4 (IN:[1043..1045] by)
                (ADVP-EXT (CD:[1046..1048] 86) (HYPH:[1048..1049] -)
                  (ADVP-1 (-NONE-:[1049..1049] *RNR*)))))
            (CC:[1050..1053] and)
            (VP
              (NP=3 (NN:[1054..1057] AHH))
              (PP=4 (IN:[1058..1060] by)
                (ADVP-EXT (CD:[1061..1063] 56) (HYPH:[1063..1064] -)
                  (ADVP-1 (-NONE-:[1064..1064] *RNR*)))))
            (ADVP-1 (RB:[1064..1068] fold))))))
    (.:[1068..1069] .)))

;sentence 9 Span:1070..1164
;Combined  treatment with BA plus piperine further increased CYP1A1mRNA
;contents by about  25%.
;[1095..1097]:substance:"BA"
;[1103..1111]:substance:"piperine"
;[1130..1140]:substance:"CYP1A1mRNA"
;[1153..1163]:quantitative-value:"about  25%"
(SENT
  (S
    (NP-SBJ
      (NP (VBN:[1070..1078] Combined) (NN:[1080..1089] treatment))
      (PP (IN:[1090..1094] with)
        (NP (NN:[1095..1097] BA) (CC:[1098..1102] plus)
            (NN:[1103..1111] piperine))))
    (ADVP (RBR:[1112..1119] further))
    (VP (VBD:[1120..1129] increased)
      (NP (NN:[1130..1140] CYP1A1mRNA) (NNS:[1141..1149] contents))
      (PP-EXT (IN:[1150..1152] by)
        (NP
          (QP (RB:[1153..1158] about) (CD:[1160..1162] 25))
          (NN:[1162..1163] %))))
    (.:[1163..1164] .)))

;sentence 10 Span:1165..1240
;The BA-inducible AHH activity, however, registered a decrease of about 45%.
;[1169..1171]:substance:"BA"
;[1182..1185]:substance:"AHH"
;[1230..1239]:quantitative-value:"about 45%"
(SENT
  (S
    (NP-SBJ (DT:[1165..1168] The)
      (ADJP (NN:[1169..1171] BA) (HYPH:[1171..1172] -)
            (JJ:[1172..1181] inducible))
      (NN:[1182..1185] AHH) (NN:[1186..1194] activity))
    (,:[1194..1195] ,)
    (ADVP (RB:[1196..1203] however))
    (,:[1203..1204] ,)
    (VP (VBD:[1205..1215] registered)
      (NP
        (NP (DT:[1216..1217] a) (NN:[1218..1226] decrease))
        (PP (IN:[1227..1229] of)
          (NP
            (QP (RB:[1230..1235] about) (CD:[1236..1238] 45))
            (NN:[1238..1239] %)))))
    (.:[1239..1240] .)))

;sentence 11 Span:1242..1334
;Piperine neither destroyed CYP1A1-protein nor affected the total cellular 
;protein contents.
;[1242..1250]:substance:"Piperine"
;[1269..1283]:cyp450:"CYP1A1-protein"
;[1317..1324]:substance:"protein"
(SENT
  (S
    (NP-SBJ (NN:[1242..1250] Piperine))
    (VP (CC:[1251..1258] neither)
      (VP (VBD:[1259..1268] destroyed)
        (NP (NN:[1269..1275] CYP1A1) (HYPH:[1275..1276] -)
            (NN:[1276..1283] protein)))
      (CC:[1284..1287] nor)
      (VP (VBD:[1288..1296] affected)
        (NP (DT:[1297..1300] the) (JJ:[1301..1306] total)
            (JJ:[1307..1315] cellular) (NN:[1317..1324] protein)
            (NNS:[1325..1333] contents))))
    (.:[1333..1334] .)))

;sentence 12 Span:1335..1480
;Exposure of cultures to 0.01 to 3.0 microM 
;trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene for 24 h reduced maximum
;cellular  growth by about 50%.
;[1359..1370]:quantitative-value:"0.01 to 3.0"
;[1371..1377]:quantitative-units:"microM"
;[1379..1424]:substance:"trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene"
;[1429..1431]:quantitative-value:"24"
;[1432..1433]:quantitative-units:"h"
;[1470..1479]:quantitative-value:"about 50%"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1335..1343] Exposure))
      (PP (IN:[1344..1346] of)
        (NP (NNS:[1347..1355] cultures)))
      (PP (TO:[1356..1358] to)
        (NP
          (NML
            (QP (CD:[1359..1363] 0.01) (TO:[1364..1366] to)
                (CD:[1367..1370] 3.0))
            (NN:[1371..1377] microM))
          (NN:[1379..1424] trans-7,8-dihydroxy-7,8-dihydrobenzo-LRB-a-RRB-pyrene)))
      (PP-TMP (IN:[1425..1428] for)
        (NP (CD:[1429..1431] 24) (NN:[1432..1433] h))))
    (VP (VBD:[1434..1441] reduced)
      (NP (JJ:[1442..1449] maximum) (JJ:[1450..1458] cellular)
          (NN:[1460..1466] growth))
      (PP-EXT (IN:[1467..1469] by)
        (NP
          (QP (RB:[1470..1475] about) (CD:[1476..1478] 50))
          (NN:[1478..1479] %))))
    (.:[1479..1480] .)))

;sentence 13 Span:1481..1558
;Piperine at 60 microM offered full protection against the  diol
;cytotoxicity.
;[1481..1489]:substance:"Piperine"
;[1493..1495]:quantitative-value:"60"
;[1496..1502]:quantitative-units:"microM"
;[1540..1544]:substance:"diol"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1481..1489] Piperine))
      (PP (IN:[1490..1492] at)
        (NP (CD:[1493..1495] 60) (NN:[1496..1502] microM))))
    (VP (VBD:[1503..1510] offered)
      (NP
        (NP (JJ:[1511..1515] full) (NN:[1516..1526] protection))
        (PP (IN:[1527..1534] against)
          (NP (DT:[1535..1538] the) (NN:[1540..1544] diol)
              (NN:[1545..1557] cytotoxicity)))))
    (.:[1557..1558] .)))

;sentence 14 Span:1559..1829
;The results, suggest that piperine mediated inhibition of the  AHH activity
;and consequent suppression of the procarcinogen activation is the  result of
;direct interaction of piperine with CYP1A1-protein and not because of  down
;regulation of the CYP1A1 gene expression.
;[1585..1593]:substance:"piperine"
;[1622..1625]:substance:"AHH"
;[1669..1682]:substance:"procarcinogen"
;[1734..1742]:substance:"piperine"
;[1748..1762]:cyp450:"CYP1A1-protein"
;[1806..1812]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ (DT:[1559..1562] The) (NNS:[1563..1570] results))
    (,:[1570..1571] ,)
    (VP (VBP:[1572..1579] suggest)
      (SBAR (IN:[1580..1584] that)
        (S
          (NP-SBJ
            (NP
              (NP
                (ADJP (NN:[1585..1593] piperine) (VBN:[1594..1602] mediated))
                (NN:[1603..1613] inhibition))
              (PP (IN:[1614..1616] of)
                (NP (DT:[1617..1620] the) (NN:[1622..1625] AHH)
                    (NN:[1626..1634] activity))))
            (CC:[1635..1638] and)
            (NP
              (NP (JJ:[1639..1649] consequent) (NN:[1650..1661] suppression))
              (PP (IN:[1662..1664] of)
                (NP (DT:[1665..1668] the) (NN:[1669..1682] procarcinogen)
                    (NN:[1683..1693] activation)))))
          (VP
            (VP (VBZ:[1694..1696] is)
              (NP-PRD=1
                (NP (DT:[1697..1700] the) (NN:[1702..1708] result))
                (PP (IN:[1709..1711] of)
                  (NP
                    (NP (JJ:[1712..1718] direct) (NN:[1719..1730] interaction))
                    (PP (IN:[1731..1733] of)
                      (NP (NN:[1734..1742] piperine)))
                    (PP (IN:[1743..1747] with)
                      (NP (NN:[1748..1754] CYP1A1) (HYPH:[1754..1755] -)
                          (NN:[1755..1762] protein)))))))
            (CC:[1763..1766] and)
            (VP (RB:[1767..1770] not)
              (PP-PRD=1 (IN:[1771..1778] because) (IN:[1779..1781] of)
                (NP
                  (NP (RB:[1783..1787] down) (NN:[1788..1798] regulation))
                  (PP (IN:[1799..1801] of)
                    (NP (DT:[1802..1805] the) (NN:[1806..1812] CYP1A1)
                        (NN:[1813..1817] gene) (NN:[1818..1828] expression))))))))))
    (.:[1828..1829] .)))

;section 15 Span:1833..1877
;PMID: 8561796 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1833..1837] PMID) (::[1837..1838] :) (CD:[1839..1846] 8561796)
        (NN:[1847..1848] -LSB-) (NNP:[1848..1854] PubMed) (::[1855..1856] -)
        (NN:[1857..1864] indexed) (IN:[1865..1868] for)
        (NNP:[1869..1877] MEDLINE-RSB-)))
